The suit alleges the Seattle-based biotech misled investors regarding its funds and the effectiveness of some of its ...

Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

Sana Biotechnology Inc. concealed from investors that it was running low on money to continuing developing drug candidates ...

Sana Biotechnology, Inc.’s SANA share price has dipped by 11.16%, which has investors questioning if this is right time to ...

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to ...

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to ...

Sana Biotechnology ( NASDAQ: SANA) was upgraded to Market Outperform from Market Perform at Citizens as the research broker ...

Sana is enrolling patients in both the GLEAM and VIVID trials and expects to share data from each study in 2025. in vivo CAR T cells – SG299, which uses our fusogen platform, allows for cell ...

Corient Private Wealth LLC increased its position in Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) by 161.7% in the fourth quarter, according to its most recent disclosure with the SEC. The ...

Sana Biotechnology, Inc. announced encouraging preliminary results from a 12-week clinical study involving hypoimmune-modified pancreatic islet cells for type 1 diabetes, showing persistent C ...

The suit alleges the Seattle-based biotech misled investors regarding its funds and the effectiveness of some of its treatment candidates. Seattle-based Sana Biotechnology Inc. (Nasdaq ...